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curves were constructed. RESULTS: Eplerenone added incre-
mental beneﬁt on mortality and morbility above placebo. Costs
was $US1279.70 higher in the eplerenone treatment (CI 95%,
$US604-1992) because of the drug cost. For eplerenone versus
placebo, the incremental cost—effectiveness ratio (ICER) was
$US13,169.8 per LYG and $US19,753.4 per QALY gained.
Using a willingness-to-pay threshold of $US20,000 per LYG or
QALY gained, 64.3% of estimates fell below this threshold.
CONCLUSION: Eplerenone compared with placebo in the treat-
ment of heart failure after AMI is effective in reducing mortal-
ity and is cost—effective with a threshold of $US20.000 per LYG
in Mexico. These results should be taken into account by
Mexican decision makers and clinicians in the management of
patients with left ventricular systolic dysfunction and heart
failure following AMI.
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OBJECTIVES: To evaluate the cost-effectiveness of lipid-lower-
ing therapy for cardiovascular disease based upon the event risk
and LDL-C reduction relationship observed in the Clinical Treat-
ment Trialists (CTT) meta-analysis. METHODS: A simple
Markov model comparing the incremental cost-effectiveness for
two lipid-lowering therapies was developed using TreeAge® soft-
ware. The addition of ezetimibe to simvastatin 40 mg was com-
pared to doubling the simvastatin 40 mg dose from the UK health
plan perspective. Patients enter the model as a primary or sec-
ondary CHD prevention patient. Patients experience a fatal or
non-fatal CHD event, die from another cause, or remain event-
free in each annual cycle. Transition probabilities were deter-
mined by a patient’s baseline risk, age and LDL-C reduction.
Lipid therapy was assumed to provide a 23% reduction in major
coronary events for 1 mmol/L reduction in LDL-C. Costs and
utilities for health states were adapted from the NICE report on
statin therapies and were discounted at 3.5%. Base case analy-
ses were performed for a 55 year old individual, with or without
a history of CHD, annual CHD risk of 3%, and a baseline LDL-
C value of 4 mmol/L. Probabilistic sensitivity analysis (PSA) was
performed and acceptability curves were generated. RESULTS:
The incremental cost per QALY gained of simvastatin/ezetimibe
co-administration was estimated at ≤14,618 and ≤18,549 for
those with and without a history of CHD, respectively. PSA
based upon 10,000 iterations suggest that the ezetimibe co-
administration was below a threshold of ≤30,000/QALY gained
in over 95% of the simulations. Additional analyses suggest that
cost effectiveness of the addition of ezetimibe improves relative
to doubling of statin dose with increasing baseline CHD risk
and/or LDL-C levels. CONCLUSION: The model developed
provides a simple method to compare two treatments based on
their effects on LDL-C. Although the model has several simpli-
fying assumptions it provided results consistent with other CHD
models.
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OBJECTIVES: Cholesterol management guidelines recommend
management of elevated low-density cholesterol (LDL-C) fol-
lowed by management of low high-density cholesterol (HDL-C)
and elevated triglycerides in patients with dyslipidemia. The
objective of this study was to conduct a population-based 
cost-efﬁcacy analysis of dyslipidemic agents using data from 
the National Health and Nutrition Examination Survey III
(NHANES III). METHODS: A 6-month, cost-effectiveness
analysis, from a MCO perspective, incorporating dose escalation
and adverse drug effects (ADEs) associated with pravastatin,
simvastatin, ezetimibe/simvastatin, and extended release (ER)
niacin/lovastatin was conducted. Patients with high LDL-C and
low HDL-C from NHANES III were included to estimate pop-
ulation values for lipids, while product labeling was used 
for lipid changes. Goals for LDL-C were <100 mg/dL and 
<130 mg/dL based on cardiovascular risk; and, HDL-C > 40 or
50 mg/dL (males and females, respectively). Medication (WAC),
physician ofﬁce visits, and laboratory costs (Medicare’s
allowance fees) were included. Monte Carlo simulations were
conducted for probabilistic sensitivity analyses testing key
assumptions of drug efﬁcacy, ADEs, and costs. RESULTS: Rates
of lipid goal achievement was a function of sex, age and treat-
ment. Accounting for dosing and ADEs, the lowest cost for 180
days of treatment was ezetimibe/simvastatin ($561), followed by
ER niacin/lovastatin ($655), pravastatin ($698), and simvastatin
($742). Attainment of LDL-C and HDL-C goals was highest for
ER niacin/lovastatin (77.8%), followed by for ezetimibe/simvas-
tatin (50.1%), simvastatin (44.2%) and pravastatin (29.5%).
Cost/patient achieving combined goals was $842 for ER
niacin/lovastatin, $1120 for ezetimibe/simvastatin, $1677 for
simvastatin, and $2364 for pravastatin. Both pravastatin and
simvastatin were dominated by ezetimibe/simvastatin, while the
incremental cost-effectiveness for ER niacin/lovastatin at $341
per additional patient reaching goal was on the cost-effective
frontier. CONCLUSION: This analysis suggests among patients
with high LDL-C and low HDL-C treatment with ezetimibe/sim-
vastatin and ER niacin/lovastatin are cost-effective strategies
compared to either pravastatin or simvastatin.
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OBJECTIVES: To estimate the cost per patient successfully
treated to NCEP ATP-III goal with high-potency statins or
statin/combinations. METHODS: We constructed a decision
analytic model (from the payer perspective) comparing four
statins or statin combinations: atorvastatin (40–80 mg), rosu-
vastatin (10–40 mg), simvastatin/ezetimibe (Vytorin; 10/10–
10/40 mg), and simvastatin 80 mg. Costs were based on best
available Military Health System (MHS) prices, and only
included drug acquisition costs. Monte Carlo methods were used
to generate a distribution of starting LDL values for a hypo-
thetical cohort of 1000 patients. The mean starting LDL was
189.1 (SD = 18.6), with individual patient LDLs normally dis-
tributed. The percentage of patients in each NCEP ATP-III risk
group was: low risk 41% (LDL goal <160 mg/dl), moderate risk
30% (LDL goal <130 mg/dl), high risk 29% (LDL goal <100
mg/dl). Distributions of efﬁcacy values (% LDL reduction) based
on clinical literature were generated for each treatment arm. The
primary outcome was the percentage of patients successfully
treated to individual NCEP ATP-III goals based on starting LDL
